


MNBS 2014 21-22 October 2014, LAAS-CNRS, Toulouse

## **Outline**



- Project's goal and consortium
- User's needs and unique value
- Innovation process and road to exploitation
- Distance to the market




## Project Objectives and consortium



Objectives: The PodiTrodi project aims to overcome the draw-backs of current Point-of-Care tests by developing technologies for really integrated (but low-cost) sample preparation. The prototype to be developed as proof of concept demonstrator will be a self-contained device that heterogeneously integrates microsystems (biosensors and microfluidics), and control electronics. The device is controlled by a portable instrument including sensor read-out, human-machine interface,embedded processor and power supply, suitable for point- of-care diagnosis of Chagas' Disease.

#### Partners:







# User's needs and unique value (1/2)



- A simple **diagnostic test** for detecting both the *Chagas' parasite* and the *host's immune response* to be used in low-resource settings and little-to-none skills of the operator.
- **Point of contact with end user**: Fiocruz laboratories are one of the possible end users; in addition they are in permanent contact with other laboratories with low resources which are potential end users.
- **Product promotion**: the advantages of the solution are explained using specification, promotional materials and pre-series prototypes which are objectives of validation during the testing phase.
- Position of users: final and integrator.
- Unique value of the solution on the market:
- 1. it brings together two complementary technologies that are essential for the correct diagnostic of the disease phase;
- 2. the development partners are in close contact with the users.





# User's needs and unique value (2/2)



- Response to user's needs: via direct inquiry and participation in the development of the experimental process.
- The Poditrodi solution aims to allow for point of care diagnostic in delocalized places at a competitive cost to industrial large scale laboratories without the need of trained personell

We target **Chagas disease** as first case scenario but we aim to classical laboratory analysis of DNA and RNA for applications ranging from medical diagnostics to environmental control and food production.

The system is designed for easy use by **unskilled personnel** as a point-of-care instrument.

Compared with standard lab instrumentation, the **lower price** (per single run) eliminates the need to perform a batch of tests in order to be cost effective.



# Innovation process and road to exploitation Process



- Road to exploitation: licensing or partnership. We are establishing a common IP strategy among partners.
- Technology validation through end users field test on real samples
- Completed **cost study** on all expected industrial production steps
- Preparation of informative material
- Customers acceptance study through questionnaires
- Market pervasion starting from selected early adopters



## **Market Penetration**



Early release:

A few adopters of R&D centers and delocalized diagnostic centers



#### **Penetration:**

Adoption by big hospitals and delocalized centers within the countries of the early adopters, 1-1.5 years



#### **Expansion:**

Adoption by R&D and medical institutions over Suoth America and other

### **Competition:**

- ► No comparable tools currently available
- ► No data about comparable on-going developments
- ▶ 2.5 years for follow-up technology development
- ► 2.5 years for clinical validation

### Distance to the market



- We are ready for early adopters test field
- We are about <u>12-18 months from the market</u> (time necessary for finishing validation and performing a basic stability validation study).
- Identification of non-technical steps. Discussion with users ongoing.
- Manufacturing. Yes, we know who and how we can manufacture the components.
- Completed <u>cost estimates</u> for the final industrial solution for low, mid and high volumes
- Access to the market: Yes, one of the partners has direct access to the market.

